Fig. 6From: Real-world clinicopathological features and outcome of thymic neuroendocrine tumors: a retrospective single-institution analysisUnivariate analysis of overall survival in thymic neuroendocrine tumor patients with Masaoka–Koga stage III/IV disease. A Radical resection. B Vessel/pericardium dissection. C Neoadjuvant therapy. D EAS comorbidity. EAS, ectopic adrenocorticotropic hormone syndromeBack to article page